Company
Therapeutic Areas
Our Pipeline
News
Careers
Contact Us
Select Year
2025
2024
2023
2022
2025.06.04
NeuShen Therapeutics to Attend Global Biopharma Leadership Forum 2025
2024.05.28
An Interview with CEO Dr. Joan Shen: Starting a CNS Venture in an Economic Downturn
2024.04.30
NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia
2024.04.18
NeuShen Therapeutics Announces Four Presentations at the 27th ASGCT Annual Meeting
2024.03.11
NeuShen Therapeutics Granted NMPA-CDE IND Approval for Highly Selective KCNQ2/3 Activator
2023.12.27
NeuShen Therapeutics Announces NMPA-CDE Acceptance of IND Application for Highly Selective KCNQ2/3 Activator
2023.10.24
NeuShen Therapeutics-UMass Chan ALS Program to Present Pre-Clinical Data at ESGCT 2023
2023.10.20
NeuShen Therapeutics Hosted Special Event Featuring Top Gene Therapy and Clinical Psychiatry Experts
2023.09.27
NeuShen Therapeutics Announces Poster Presentation of a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia at Neuroscience 2023
2023.08.03
NeuShen Therapeutics Announces Poster Presentation of Novel KCNQ2/3 Selective Activator NS-041 at ACS FALL 2023
About Us
Mission & Culture
Leadership Team
Depression
Schizophrenia
Neurological Disorders
Pipeline
Clinical Trials
Publications
Copyright © 2025 NeuShen Therapeutics, Inc. All rights reserved.
